Pasithea Therapeutics Corp KTTA

$0.50 -0.02 (-4.21%)

Valuation

Market cap
17,442,000
Revenue TTM
$0
Net income TTM
$-20,430,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
944,200
Avg volume
788,574
Day's range
$0.43 – $0.52
Shares out
33,414,000
Stochastic %K
37%
Beta
0.39
Analysts
Moderate Buy
Price target
$3.00

Price

Company profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven...

Show more

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
786 977 3380
Website
https://www.pasithea.com
Address
1111 Lincoln Road, Suite 500, Miami Beach, United States

Latest news

No headlines yet.